标题
Ramucirumab: A Review in Hepatocellular Carcinoma
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 3, Pages 315-322
出版商
Springer Science and Business Media LLC
发表日期
2020-02-07
DOI
10.1007/s40265-020-01263-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) A Vogel et al. ANNALS OF ONCOLOGY
- Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
- (2019) Teiji Kuzuya et al. HEPATOLOGY RESEARCH
- Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
- (2019) Peter Galle et al. JOURNAL OF HEPATOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
- (2019) Robert Montal et al. BRITISH JOURNAL OF CANCER
- Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
- (2019) Peter R. Galle et al. LIVER INTERNATIONAL
- 757PEfficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
- (2019) M Kudo et al. ANNALS OF ONCOLOGY
- 753PPrognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
- (2019) A X Zhu et al. ANNALS OF ONCOLOGY
- 758PRamucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
- (2019) J Llovet et al. ANNALS OF ONCOLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- 149OEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
- (2018) Y-K Kang et al. ANNALS OF ONCOLOGY
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
- (2017) Hiroshi Nokihara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
- (2017) Junning Cao et al. ONCOLOGIST
- Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
- (2016) Ran Xu Zhu et al. Gut and Liver
- Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
- (2015) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now